创伤性脑损伤中凝血障碍与颅内出血进展:机制、影响与治疗考虑
本文为选择性文献综述,基于Medline(PubMed)和Cochrane Reviews数据库,回顾TBI后凝血障碍与出血性进展的频率、模式、机制、诊断新方法、治疗及结局。约20%的孤立性TBI患者入院时存在实验室凝血障碍,对发病率和死亡率有深远影响。伤前使用抗血栓药物可能与更高的出血性进展和迟发性创伤性颅内出血率相关。
要点
- 约20%孤立性TBI患者入院时存在实验室凝血障碍,显著影响预后。
- 伤前使用抗血栓药物可能与出血性进展和迟发性颅内出血率升高相关。
- 黏弹性及凝血酶生成等全局止血检测或可指导早期目标导向治疗。
核心结论
- 及时针对性管理TBI后止血异常能否防止继发性脑损伤并改善结局仍不明确。
研究设计与样本
- 选择性文献综述,检索Medline(PubMed)和Cochrane Reviews数据库,使用相关检索词的不同组合。
主要发现
- 约20%的孤立性TBI患者入院时显示实验室凝血障碍,对发病率和死亡率有深远影响。
- 伤前使用抗血栓药物可能与更高的出血性进展率和迟发性创伤性颅内出血率相关。
- 进一步检测可能显示影响血小板功能/数量、促凝和/或抗凝因子、纤溶以及脑组织、血管内皮、炎症机制和血流动力学之间相互作用的各种变化。
- TBI后止血紊乱的性质仍难以捉摸,但当前证据提示存在高凝和低凝状态,可能重叠且缺乏阶段和状态间的区分。
- 黏弹性和凝血酶生成等更「全局」的止血检测可能提供更详细和及时的总体止血潜力信息,从而允许早期「目标导向」治疗。
临床怎么用
- 可考虑使用黏弹性或凝血酶生成等全局止血检测获取总体止血潜力信息,以支持早期目标导向治疗。
局限性
- 本文为选择性文献综述,非系统评价。
- TBI后止血紊乱的性质仍难以捉摸,高凝与低凝状态可能重叠且缺乏阶段区分。
- 及时针对性管理止血异常能否防止继发性脑损伤并改善结局仍不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Traumatic brain injury (TBI) remains one of the most challenging health and socioeconomic problems of our times. Clinical courses may be complicated by hemostatic abnormalities either pre-existing or developing with TBI. OBJECTIVE: To review frequencies, patterns, mechanisms, novel approaches to diagnostics, treatment, and outcomes of hemorrhagic progression and coagulopathy after TBI. METHODS: Selective review of the literature in the databases Medline (PubMed) and Cochrane Reviews using different combinations of the relevant search terms was conducted. RESULTS: Of the patients, 20% with isolated TBI display laboratory coagulopathy upon hospital admission with profound effect on morbidity and mortality. Preinjury use of antithrombotic agents may be associated with higher rates of hemorrhagic progression and delayed traumatic intracranial hemorrhage. Further testing may display various changes affecting platelet function/numbers, pro- and/or anticoagulant factors, and fibrinolysis as well as interactions between brain tissues, vascular endothelium, mechanisms of inflammation, and blood flow dynamics. The nature of hemostatic disruptions after TBI remains elusive but current evidence suggests the presence of both a hyper- and hypocoagulable state with possible overlap and lack of distinction between phases and states. More "global" hemostatic assays, eg, viscoelastic and thrombin generation tests, may provide more detailed and timely information on the overall hemostatic potential thereby allowing early "goal-directed" therapies. CONCLUSION: Whether timely and targeted management of hemostatic abnormalities after TBI can protect against secondary brain injury and thereby improve outcomes remains elusive. Innovative technologies for diagnostics and monitoring offer windows of opportunities for precision medicine approaches to managing TBI.
引用
- Maegele M. Coagulopathy and Progression of Intracranial Hemorrhage in Traumatic Brain Injury: Mechanisms, Impact, and Therapeutic Considerations. Neurosurgery. 2021. PMID: 34676410. doi:10.1093/neuros/nyab358
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。